Prostate Cancer Therapeutics Market Size Worth US$ 8,191.11 million | 7.5% CAGR By 2027 – By Coherent Market Insights
Prostate Cancer Therapeutics Market report provides key enumeration on the Market status of the Prostate Cancer Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using an objective combination of primary and secondary information including inputs from key participants in the Prostate Cancer Therapeutics industry. It delivers important information to identify and analyse the market need, market Growth and competition.
The global Prostate Cancer Therapeutics Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Prostate Cancer Therapeutics Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.
Prostate cancer is a serious health issue among men and has a large socioeconomic impact on the society. Almost all types of prostate cancer are adenocarcinomas. Other types, such as transitional cell carcinomas, neuroendocrine tumors, small cell carcinomas, and sarcomas are rare. Advanced prostate cancer occurs when it has spread, or metastasized, from the prostate to other areas of the body. This may cause men to urinate more often or have a weak flow of urine, but these symptoms can also be caused by benign prostate conditions. Prostate cancer is the second leading cause of cancer death in American men, and thus, there is an increasing demand for prostate cancer therapeutics in this region.
Increasing prevalence of prostate cancer worldwide, especially in the United States, is expected to propel the growth of the prostate cancer therapeutics market over the forecast period. For instance, according to the American Community Survey, in 2016, prostate cancer was the second leading cause of death in men in the U.S.
Moreover, growing geriatric population worldwide is expected to drive growth of the prostate cancer therapeutics market. The incidence rate of prostate cancer is higher in older men. For instance, according to the National Cancer Registry Ireland, 2011, in Ireland, median age for prostate cancer diagnosis was 67 years with 38.9% of cases being diagnosed in men and 21.3% in men aged 75 years and older.
Furthermore, introduction of highly effective therapeutics for prostate cancer is expected to aid in the growth of the prostate cancer therapeutics market. Many pharma companies, universities, and research organizations are focused on developing or introducing novel therapeutics for prostate cancer. For instance, in December 2016, the Scottish Medicines Consortium (SMC) approved Sanofi’s Jevtana (cabazitaxel) for routine use in NHS Scotland to treat metastatic hormone-refractory prostate cancer (mHRPC).
High cost associated with drugs and poor reimbursement policies are expected to hinder growth of the prostate cancer therapeutics market.
North America is expected to witness robust growth in the prostate cancer therapeutics market due to the increasing prevalence of prostate cancer and rising aging population in this region. For instance, according to the American Cancer Society (ACS), around 161,360 Americans are expected to have prostate cancer in 2017, leading to around 26,730 fatalities. Moreover, ACS and the National Comprehensive Cancer Network (NCCN) recommends that all men over the age of 40 should have an annual rectal exam and men (aged 50 years) have an annual prostate-specific antigen (PSA) test.
By Drug Type:
By Distribution Channel:
Middle East and Africa
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/1257
Reasons to Purchase this Report
• Current and future of global Prostate Cancer Therapeutics Market outlook in the developed and emerging markets
• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
• Regions/countries that are expected to witness the fastest growth rates during the forecast period
• The latest developments, market shares, and strategies that are employed by the major market players
Prostate Cancer Therapeutics Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire